Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
News|Articles|September 8, 2026
Monthly pipeline update: August 2026
Author(s)Anita Shiva
Fact checked by: Kirsty Mackay
The latest in drug and technology developments and updates from August 2026.
Advertisement
Advertisement
This August, the long-awaited approval of Lytenava (bevacizumab-vikg; Outlook Therapeutics) changed the landscape of neovascular age-related macular degeneration (AMD) treatment. Major updates in dry eye, lens technology, and glaucoma treatment also took the spotlight. Learn the latest in pipeline news from our roundup below:
Related to this article
Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, details his AAOpt 2026 presentation "Photobiomodulation in Age-Related Macular Degeneration: Evidence, Mechanisms, and Clinical Integration."
Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.
Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Advertisement
Advertisement